December 20, 2024

Long COVID Shows Five Distinct Patterns: Study

In the 2024 update, the NIH's RECOVER Initiative identified five distinct symptom patterns and new diagnostic thresholds for long COVID.

Conexiant

December 20, 2024

FDA Approves New Cystic Fibrosis Drug

Vertex Pharmaceuticals' groundbreaking next-generation treatment for cystic fibrosis, Alyftrek, has been approved by the FDA, promising to revolutionize the management of this rare genetic disease.

Reuters

December 16, 2024

FDA 6-Month Drug Pipeline

A pipeline of novel drugs awaits FDA review through the first half of 2025.

Conexiant

December 16, 2024

Smoke Travels 2,100 Miles, Hits Heart Health

A case-only study published in JAMA Network Open reveals a significant increase in cardiopulmonary clinical encounters in Maryland during June 2023, associated with remote wildfire smoke exposure, extending beyond the immediate wildfire vicinity.

Conexiant

December 16, 2024

AAP Unveils Screening Protocol Changes

New guidelines for congenital heart disease screening recommend a single retest and require ≥95% oxygen saturation in both pre- and post-ductal measurements, aiming to simplify detection while maintaining accuracy.

Conexiant

December 13, 2024

New Vaccine Prevents Severe RSV Illness

A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.

Conexiant

December 13, 2024

Air Pollution Tied to Blood Clots in Veins

In a 17-year study of over 6,600 adults, researchers found that for every 3.6 µg/m3 increase in PM2.5 exposure, VTE risk increased by 39%, with even stronger associations observed in the first decade of follow-up.

Conexiant

December 05, 2024

AHA: Smokeless Nicotine's CVD Risks

New data reveals smokeless oral nicotine products show lower cardiovascular risks than cigarettes but are associated with increased mortality in patients with existing heart conditions.

Conexiant

December 03, 2024

Roivant Ends Lung Drug After Trial

Roivant discontinues injectable drug namilumab for treating chronic active pulmonary sarcoidosis, citing failure to show treatment benefits in mid-stage trial.

Reuters